Heads of HTA Agencies Group convene in Lisbon for fourth meeting

By HEOR Staff Writer

January 18, 2023

HTA Agencies Meeting Updates

HTA Agencies Meeting Updates: It seems the Heads of HTA Agencies Group had a productive meeting in Lisbon, Portugal. They discussed key strategic topics including the confirmation of the new Vice-Chair, updates on the HTA Regulation and long-term strategic planning for the group!

Next meeting will take place in Stockholm, Sweden in May 2023.

Reference url

Recent Posts

Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...
Factor XIa Inhibition Stroke
Advancements in Factor XIa Inhibition Stroke Prevention Through Asundexian

By HEOR Staff Writer

June 10, 2026

The European Medicines Agency has accepted Bayer’s marketing authorization application for asundexian, marking a major advance in Factor XIa Inhibition Stroke prevention. This oral agent selectively interrupts a key step in the coagulation cascade to reduce recurrent ischemic stroke risk in adult...
Tovorafenib clinical assessment
Tovorafenib Clinical Assessment Outcomes and Methodological Challenges

By João L. Carapinha

June 9, 2026

The Tovorafenib clinical assessment conducted under the EU Joint Clinical Assessment process has exposed critical shortcomings in the evidence base for treating BRAF-altered pediatric low-grade glioma. Despite the therapy’s potential, reviewers concluded that robust comparative data is absent for...